chiniofon and Anemia--Sickle-Cell

P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin-blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.

Topics: Anemia, Sickle Cell; Blood Flow Velocity; Cell Adhesion; Endothelial Cells; Endothelium, Vascular; Glycolipids; Humans; Hydroxyquinolines; P-Selectin; Pentosan Sulfuric Polyester